CP
BMRN icon

Castleview Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Castleview Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-400
Closed -$26.6K – 223
2024
Q4 		$26.6K Hold
400
– – 0.01% 431
2024
Q3 		$28.1K Hold
400
– – 0.02% 402
2024
Q2 		$32.9K Hold
400
– – 0.02% 378
2024
Q1 		$34.9K Hold
400
– – 0.02% 388
2023
Q4 		$38.6K Hold
400
– – 0.03% 355
2023
Q3 		$35.4K Buy
+400
New +$35.6K 0.03% 315

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Castleview Partners's BMRN Position: Q1 2025 in Review

Castleview Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 400 shares — an estimated $26.6K sold.

Castleview Partners first reported a position in BMRN in Q3 2023 and held it in 6 quarters. The position peaked at $38.6K in Q4 2023. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

  • Castleview Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Castleview Partners sold 400 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $26.6K.
  • Castleview Partners first reported a position in BioMarin Pharmaceuticals in Q3 2023 and held it in 6 quarters.
  • Castleview Partners's BioMarin Pharmaceuticals position peaked at $38.6K in Q4 2023.
  • 584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Castleview Partners's 13F filing for Q1 2025, filed 22 Apr 2025.